136
Participants
Start Date
October 1, 2020
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2023
Enteral contrast challenge
Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
Children's Medical Center of Dallas, Dallas
Children's Hospital Colorado, Aurora
Primary Children's Hospital, Salt Lake City
Phoenix Children's Hospital, Phoenix
Children's Hospital Los Angeles, Los Angeles
Rady Children's Hospital, San Diego
UCSF Benioff Children's Hospital, Oakland
Oregon Health Sciences University, Portland
Seattle Children's Hospital, Seattle
Children's Hospital Los Angeles
OTHER
University of California, San Francisco
OTHER
Oregon Health and Science University
OTHER
Rady Children's Hospital, San Diego
OTHER
Phoenix Children's Hospital
OTHER
Primary Children's Hospital
OTHER
Children's Medical Center Dallas
OTHER
Seattle Children's Hospital
OTHER
Children's Hospital Colorado
OTHER